Should I Buy VALN? VALN 2026 Analysis

Should You Buy Valneva SE (VALN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

9.410

1 Day change

52 Week Range

12.250

Analysis Updated At

2026/01/26

Valneva SE (VALN) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The recent regulatory challenges, including the withdrawal of its vaccine applications due to FDA suspension, significantly impact the company's growth prospects and revenue expectations. Additionally, there are no strong technical or proprietary trading signals to suggest an immediate buying opportunity.

Technical Analysis

The stock's MACD is positive but contracting, RSI is neutral at 47.35, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below the pivot point (9.993) in pre-market at 9.75, indicating potential bearish sentiment. Support levels are at 9.707 and 9.53, with resistance at 10.28 and 10.457.

Options Data

Positive Catalysts

NULL identified.

Neutral/Negative Catalysts

The FDA's suspension of Valneva's IXCHIQ vaccine license and the subsequent withdrawal of its Biologics License Application and IND application in the U.S. pose significant regulatory and revenue challenges.

Financial Performance

Financial data unavailable for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

2 Analyst Rating

Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is 10.28 USD with a low forecast of 7.55 USD and a high forecast of 13 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 9.410

Low

7.55

Averages

10.28

High

Current: 9.410

Low

7.55

Averages

10.28

High

Guggenheim

Buy

downgrade

$14 -> $13

AI Analysis

2025-09-08

Reason

Guggenheim

Price Target

$14 -> $13

AI Analysis

2025-09-08

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Valneva to $13 from $14 and keeps a Buy rating on the shares following the company's recent first half earnings release and the suspension of the Ixchiq BLA in the U.S. Given the suspension, the firm is removing all U.S. Ixchiq sales from its model and also assumes more limited commercial uptake in Europe, but it maintains a Buy rating ahead of the "important" Phase 3 data readout for their Lyme vaccine that it expects by late Q4 or in early Q1 of 2026.

Jefferies

Maury Raycroft

Buy

downgrade

$18 -> $14

2025-08-25

Reason

Jefferies

Maury Raycroft

Price Target

$18 -> $14

2025-08-25

downgrade

Buy

Reason

Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 and keeps a Buy rating on the shares after the FDA suspended the Ixchiq biologics license application based on four new serious adverse events seen outside of the U.S. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, adds that Ixchiq is "not a major revenue driver" in the near term.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VALN

Unlock Now

VALN Should I Buy

VALN Should I Buy

Should You Buy Valneva SE (VALN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch